These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 36194789)

  • 1. PDE5 inhibitors and male reproduction: Is there a place for PDE5 inhibitors in infertility clinics or andrology laboratories?
    Dimitriadis F; Kaltsas A; Zachariou A; Mamoulakis C; Tsiampali C; Giannakis I; Paschopoulos M; Papatsoris A; Loutradis D; Tsounapi P; Takenaka A; Sofikitis N
    Int J Urol; 2022 Dec; 29(12):1405-1418. PubMed ID: 36194789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effect of PDE5 Inhibitors on the Male Reproductive Tract.
    Sofikitis N; Kaltsas A; Dimitriadis F; Rassweiler J; Grivas N; Zachariou A; Kaponis A; Tsounapi P; Paterakis N; Karagiannis A; Skouros S; Giannakis I; Champilomatis I; Paschopoulos M; Daphnis D; Giakoumakis I; R Gabales M; M Chua JB; Lantin Iii PL; Mamoulakis C; Takenaka A
    Curr Pharm Des; 2021; 27(23):2697-2713. PubMed ID: 32101115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of phosphodiesterase-5 inhibitors on sperm parameters and fertilizing capacity.
    Dimitriadis F; Giannakis D; Pardalidis N; Zikopoulos K; Paraskevaidis E; Giotitsas N; Kalaboki V; Tsounapi P; Baltogiannis D; Georgiou I; Saito M; Watanabe T; Miyagawa I; Sofikitis N
    Asian J Androl; 2008 Jan; 10(1):115-33. PubMed ID: 18087651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is there a role for PDE5 inhibitors in the management of male infertility due to defects in testicular or epididymal function?
    Dimitriadis F; Tsounapi P; Saito M; Watanabe T; Sylakos A; Tsabalas S; Miyagawa I; Sofikitis N
    Curr Pharm Des; 2009; 15(30):3506-20. PubMed ID: 19860697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphodiesterase 5 (PDE-5) inhibitors (sildenafil, tadalafil, and vardenafil) effects on esophageal motility: a systematic review.
    Shafiee A; Bahri RA; Teymouri Athar MM; Afsharrezaei F; Gholami M
    BMC Gastroenterol; 2023 May; 23(1):170. PubMed ID: 37217851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of phosphodiesterase-5 inhibitors on Leydig cell secretory function in oligoasthenospermic infertile men: a randomized trial.
    Dimitriadis F; Tsambalas S; Tsounapi P; Kawamura H; Vlachopoulou E; Haliasos N; Gratsias S; Watanabe T; Saito M; Miyagawa I; Sofikitis N
    BJU Int; 2010 Oct; 106(8):1181-5. PubMed ID: 20184572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability.
    Wang R; Burnett AL; Heller WH; Omori K; Kotera J; Kikkawa K; Yee S; Day WW; DiDonato K; Peterson CA
    J Sex Med; 2012 Aug; 9(8):2122-9. PubMed ID: 22759639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of the phosphodiesterase 5 inhibitors sildenafil, tadalafil and vardenafil on rat anococcygeus muscle: functional and biochemical aspects.
    Toque HA; Priviero FB; Zemse SM; Antunes E; Teixeira CE; Webb RC
    Clin Exp Pharmacol Physiol; 2009 Apr; 36(4):358-66. PubMed ID: 18986324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral phosphodiesterase type 5 inhibitors and male reproductive potential: an overview.
    Mostafa T; Alghobary M; Hanafy NS; Abosief A
    Sex Med Rev; 2023 Jun; 11(3):240-252. PubMed ID: 36990971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PDE5 inhibitors, sildenafil and vardenafil, reverse multidrug resistance by inhibiting the efflux function of multidrug resistance protein 7 (ATP-binding Cassette C10) transporter.
    Chen JJ; Sun YL; Tiwari AK; Xiao ZJ; Sodani K; Yang DH; Vispute SG; Jiang WQ; Chen SD; Chen ZS
    Cancer Sci; 2012 Aug; 103(8):1531-7. PubMed ID: 22578167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphodiesterase Type-5 Inhibitor Prescription Patterns in the United States Among Men With Erectile Dysfunction: An Update.
    Mulhall JP; Chopra I; Patel D; Hassan TA; Tang WY
    J Sex Med; 2020 May; 17(5):941-948. PubMed ID: 32144034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient.
    Corona G; Mondaini N; Ungar A; Razzoli E; Rossi A; Fusco F
    J Sex Med; 2011 Dec; 8(12):3418-32. PubMed ID: 21995676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.
    Gacci M; Corona G; Salvi M; Vignozzi L; McVary KT; Kaplan SA; Roehrborn CG; Serni S; Mirone V; Carini M; Maggi M
    Eur Urol; 2012 May; 61(5):994-1003. PubMed ID: 22405510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of three phosphodiesterase type 5 inhibitors on ejaculation latency time in lifelong premature ejaculators: a double-blind laboratory setting study.
    Gökçe A; Halis F; Demirtas A; Ekmekcioglu O
    BJU Int; 2011 Apr; 107(8):1274-7. PubMed ID: 21929518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of vardenafil on semen parameters in infertile men: a pilot study evaluating short-term treatment.
    Rago R; Salacone P; Caponecchia L; Marcucci I; Fiori C; Sebastianelli A
    J Endocrinol Invest; 2012 Nov; 35(10):897-900. PubMed ID: 22522672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treating erectile dysfunction and central neurological diseases with oral phosphodiesterase type 5 inhibitors. Review of the literature.
    Lombardi G; Nelli F; Celso M; Mencarini M; Del Popolo G
    J Sex Med; 2012 Apr; 9(4):970-85. PubMed ID: 22304626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nebivolol potentiates the efficacy of PDE5 inhibitors to relax corpus cavernosum and penile arteries from diabetic patients by enhancing the NO/cGMP pathway.
    Martínez-Salamanca JI; La Fuente JM; Cardoso J; Fernández A; Cuevas P; Wright HM; Angulo J
    J Sex Med; 2014 May; 11(5):1182-92. PubMed ID: 24877179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphodiesterase 5 (PDE5) inhibition, ANP and NO rapidly reduce epididymal duct contractions, but long-term PDE5 inhibition in vivo does not.
    Mietens A; Tasch S; Feuerstacke C; Eichner G; Volkmann J; Schermuly RT; Grimminger F; Müller D; Middendorff R
    Mol Cell Endocrinol; 2012 Feb; 349(2):145-53. PubMed ID: 21996373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [PDE5 inhibitors in treatment of benign prostatic syndrome].
    Sandner P; Tinel H; Stelte-Ludwig B; Huetter J; Neuser D; Bischoff E; Ulbrich E
    Urologe A; 2007 Sep; 46(9):1189-92. PubMed ID: 17609921
    [No Abstract]   [Full Text] [Related]  

  • 20. Sildenafil and cardioprotection.
    Kukreja RC
    Curr Pharm Des; 2013; 19(39):6842-7. PubMed ID: 23590161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.